MSK and NIH Scientists Develop AI Tool to Predict How Cancer Patients Will Respond to Immunotherapy
In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.
In the Lab
Clearing the Fog around Tumor Mutational Burden
MSK researchers shed light on how the number of mutations in a tumor affect a patient’s response to immunotherapy drugs.
Finding
One Patient’s Exceptional Response Leads to a Surprising Discovery about Immunotherapy
MSK researchers learn that some cancers may respond to checkpoint inhibitor drugs because of changes called gene fusions.
